We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+3.78%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$151M
AUM Growth
+$23M
Cap. Flow
+$26.2M
Cap. Flow %
17.3%
Top 10 Hldgs %
42.26%
Holding
109
New
25
Increased
23
Reduced
25
Closed
15

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$2.4M
2
PVLA
Palvella Therapeutics
PVLA
+$2.24M
3
ZBIO
Zenas BioPharma
ZBIO
+$2.05M
4
REPL icon
Replimune Group
REPL
+$2.02M
5
TECX
Tectonic Therapeutic
TECX
+$2.01M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$2.14M
2
GILD icon
Gilead Sciences
GILD
+$1.31M
3
THC icon
Tenet Healthcare
THC
+$1.21M
4
SWTX
SpringWorks Therapeutics
SWTX
+$1.12M
5
BPMC
Blueprint Medicines
BPMC
+$994K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAX
26
Bicara Therapeutics
BCAX
$1.7B
$1.87M 1.24%
+201,395
New +$2.4M
PFE icon
27
Pfizer
PFE
$143B
$1.87M 1.23%
77,150
+17,500
+29% +$408K
ONC
28
BeOne Medicines Ltd
ONC
$33.9B
$1.87M 1.23%
7,716
+4,789
+164% +$1.17M
KURA icon
29
Kura Oncology
KURA
$793M
$1.87M 1.23%
+323,572
New +$1.98M
TRML
30
DELISTED
Tourmaline Bio
TRML
$1.86M 1.23%
+116,510
New +$1.89M
ANAB icon
31
AnaptysBio
ANAB
$1.54B
$1.86M 1.23%
+83,900
New +$1.76M
TIL icon
32
Instil Bio
TIL
$49M
$1.8M 1.19%
+86,220
New +$1.8M
IMTX icon
33
Immatics
IMTX
$1.23B
$1.79M 1.18%
+332,270
New +$1.65M
BNTX icon
34
BioNTech
BNTX
$23.5B
$1.72M 1.14%
16,160
-1,015
-6% -$103K
MRK icon
35
Merck
MRK
$322B
$1.67M 1.1%
20,900
-6,000
-22% -$477K
TMO icon
36
Thermo Fisher Scientific
TMO
$214B
$1.58M 1.04%
3,900
+650
+20% +$272K
SYK icon
37
Stryker
SYK
$135B
$1.55M 1.02%
3,900
-2,200
-36% -$823K
INSM icon
38
Insmed
INSM
$22.4B
$1.5M 0.99%
14,880
-350
-2% -$26.8K
REGN icon
39
Regeneron Pharmaceuticals
REGN
$72.9B
$1.46M 0.96%
2,773
– –
SMMT icon
40
Summit Therapeutics
SMMT
$10.2B
$1.39M 0.92%
65,220
-4,020
-6% -$91.7K
AZN icon
41
AstraZeneca
AZN
$269B
$1.3M 0.86%
9,320
-75
-0.8% -$10.5K
BMRN icon
42
BioMarin Pharmaceuticals
BMRN
$11.9B
$1.29M 0.85%
23,530
– –
EW icon
43
Edwards Lifesciences
EW
$49.4B
$1.17M 0.77%
+15,000
New +$1.12M
DXCM icon
44
DexCom
DXCM
$29B
$1.15M 0.76%
13,200
-1,800
-12% -$141K
SPRY icon
45
ARS Pharmaceuticals
SPRY
$579M
$1.15M 0.76%
65,785
-34,420
-34% -$497K
ALNY icon
46
Alnylam Pharmaceuticals
ALNY
$38.3B
$1.08M 0.72%
3,323
-1,882
-36% -$521K
GPCR icon
47
Structure Therapeutics
GPCR
$3.37B
$1.07M 0.7%
51,369
+17,674
+52% +$389K
VERA icon
48
Vera Therapeutics
VERA
$2.33B
$976K 0.64%
41,418
+13,070
+46% +$294K
MRUS
49
DELISTED
Merus
MRUS
$825K 0.54%
+15,675
New +$737K
GMED icon
50
Globus Medical
GMED
$11.1B
$797K 0.53%
+13,500
New +$872K
1
2
3 4 5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Sectoral Asset Management held 109 positions worth $151M, up 18% from $128M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sectoral Asset Management deployed $26.2M of net new capital in Q2 2025, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was Bicara Therapeutics: 201,395 shares worth $1.87M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $1.31M trimmed.

  • Sectoral Asset Management's largest Q2 2025 buy was Bicara Therapeutics: 201,395 shares worth $1.87M.
  • Sectoral Asset Management added most to Arcus Biosciences in Q2 2025, an estimated $1.97M increase.
  • Sectoral Asset Management's biggest Q2 2025 reduction was Gilead Sciences, cutting an estimated $1.31M.
  • Sectoral Asset Management fully exited Medtronic in Q2 2025, selling an estimated $2.14M.
  • Sectoral Asset Management's ten largest holdings make up 42% of its $151M portfolio in Q2 2025.
  • Sectoral Asset Management opened 25 new positions and closed 15 in Q2 2025.
  • Sectoral Asset Management's portfolio value rose 18% quarter-over-quarter to $151M.

Based on Sectoral Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.